Correction in the Annual Report 2012/13
Contingent liabilities for the Group on page 86 and in note 29 on page 114 in the annual report 2012/13 is incorrect. The error is corrected in the attached version of the Annual Report. The correct figure should be according to the year-end report May-April 2012/13 and is SEK 178 M for April 30, 2013 and SEK 68 M for April 30, 2012.
For further information, please contact:
Johan Andersson, Director Investor Relations, Elekta AB.
Tel: +46 702 100 451, email: firstname.lastname@example.org.
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 08:00 CET on August 30, 2013.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.